The sodium-glucose cotransporter-2 (SGLT2) inhibitors are another drug class for T2D that have also been shown to improve cardiovascular outcomes [132], and a popular hypothesis to explain their cardioprotective actions stems from their ability to increase circulating ketones [23,133]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.